For decades Cochlear, CSL and ResMed could do no wrong. Those days are over, and a battery of issues has investors increasingly sceptical about their prospects.

The hearing implant maker’s share price cratered to the lowest level since April 2016 after it warned that softer global sales would hit its bottom line.

The ASX company said it expected underlying annual profit to fall between $290m and $330m. Previously, Cochlear had guided to a profit of between $435m and $460m and had then indicated profits would ...

Thank you for standing by, and welcome to the Cochlear Limited Half Year 2025 Results Analyst and Media Briefing. All participants are in listen-only mode. There will be presentation, followed by a ...

Cochlear’s biggest woe in an earnings downgrade relates to developed markets – notably the US which accounts for more than ..

Cuts to Medicaid legislated by Trump’s One Big Beautiful Bill Act have crippled Cochlear’s American business by restricting coverage for hearing implants. The ASX company said it expected underlying ...